chronic lymphocytic leukemia

(redirected from CLL)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
  • noun

Words related to chronic lymphocytic leukemia

chronic leukemia characterized by lymphoblast-like cells

Related Words

References in periodicals archive ?
The authors further suggest the method of CLL best suited to students requires a smaller class setting, where the instructor can better moderate and monitor the collaborations.
Anderson Cancer Center in Houston reports preliminary results from a trial of CLL patients given the experimental drug fludarabine.
We have seen remarkable advances in treatments for patients with CLL over the past two years," said Louis J.
IMBRUVICA was initially approved in February 2014 under Subpart H regulation, the FDA s accelerated approval process, based on data from a Phase 1b/2 study for patients with CLL who have received at least one prior therapy.
CLL PROFILER kit detects cytogenetic abnormalities in bone marrow specimens and peripheral blood samples from patients with CLL.
These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions - the remissions last months on end - with acceptable toxicity in relapsed and refractory CLL," Dr.
Chris West, a spokesman for cancer charity Bloodwise, said: "Coinciding with National Blood Cancer Awareness Month, Nice's recommendation of idelalisib is a very welcome development for adult patients with CLL in England and Wales, particularly when there is such uncertainty around the future availability of many blood cancer treatments.
About Chronic Lymphocytic Leukemia (CLL) and 17p Deletion CLL is a slow-progressing cancer of the bone marrow and blood in which the bone marrow makes too many lymphocytes, a type of white blood cell.
The CLL Knowledge Centre can be accessed at the following address: http://www.
Kate Smith, the recently selected general manager of Lothian Labels, will be working hand in hand with John Barrie and the CLL team; this juncture brings a wealth of much essential know-how to the speedily expanding group.
Danilov said that in this in-vitro microenvironment, we used MLN4924 to disrupt the activity of the NF-kappaB pathway by targeting Nedd8, which controls activation of NF-kappaB, asserting that this decreased the survival of CLL cells and re-sensitized them to conventional chemotherapy as well as novel agents.
In this study, we show fluorescent analysis, PCR, and Sanger sequencing results for ccf-DNA isolated by DEP from 25-[micro]L samples of unprocessed CLL patient blood.
Despite their origin from mature B cells and similar epidemiology, CLL and PCM have widely different clinical presentations, pathologic features, treatment, and outcomes.